Merck KGaA

The waxing and waning of the speedy approval
The waxing and waning of the speedy approval
EP Vantage
FDA
drug approvals
accelerated approvals
AbbVie
AstraZeneca
Bayer
Bristol Myers Squibb
JNJ
Merck
Merck KGaA
Novartis
Pfizer
Flag link:
Industry Seeks to Stimulate Innovation Through Grant Programs
Industry Seeks to Stimulate Innovation Through Grant Programs
BioSpace
grants
R&D
Thermo Fisher Scientific
Merck KGaA
Qiagen
Flag link:
Finding the big spenders beyond big pharma
Finding the big spenders beyond big pharma
EP Vantage
R&D
Amgen
Bayer
Biogen
Gilead Sciences
Merck KGaA
Moderna Therapeutics
Novo Nordisk
Regeneron Pharmaceuticals
UCB
Vertex Pharmaceuticals
Flag link:
Big pharma holds steady on research spending
Big pharma holds steady on research spending
EP Vantage
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Flag link:
Merck KGaA's multiple sclerosis drug hit with partial FDA hold, adding to BTK-liver injury links
Merck KGaA's multiple sclerosis drug hit with partial FDA hold, adding to BTK-liver injury links
Fierce Biotech
Merck KGaA
multiple sclerosis
MS
Btk inhibitors
liver damage
Flag link:
Merck KGaA takes back control of PD-L1 cancer drug as Pfizer alliance ends
Merck KGaA takes back control of PD-L1 cancer drug as Pfizer alliance ends
Endpoints
Merck KGaA
Pfizer
cancer
Bavencio
Flag link:
Merck KGaA makes its Foundry data tools available for free
Merck KGaA makes its Foundry data tools available for free
Pharmaphorum
Merck KGaA
Palantir Technologies
digital pharma
drug discovery
Foundry DevTools
Flag link:
Merck KGaA, Haleon warn of more inflation challenges in 2023
Merck KGaA, Haleon warn of more inflation challenges in 2023
Fierce Pharma
Merck KGaA
Haleon
inflation
Flag link:
Merck KGaA, spying a major market, pays Aqilion €10M to tackle tough autoimmune target
Merck KGaA, spying a major market, pays Aqilion €10M to tackle tough autoimmune target
Fierce Biotech
Merck KGaA
Aqilion
autoimmune disease
Flag link:
Layoffs continue to batter biotech, with Big Pharmas piling on the pain
Layoffs continue to batter biotech, with Big Pharmas piling on the pain
Fierce Biotech
layoffs
Amgen
Merck KGaA
TCR2 Therapeutics
Moderna Therapeutics
Flag link:
Merck KGaA shrinks U.S. research team as layoffs continue to batter industry
Merck KGaA shrinks U.S. research team as layoffs continue to batter industry
Fierce Biotech
Merck KGaA
layoffs
R&D
Flag link:
Merck KGaA hands over IL-12-targeting cancer med to PDS Biotech in $121M deal
Merck KGaA hands over IL-12-targeting cancer med to PDS Biotech in $121M deal
Fierce Biotech
Merck KGaA
R&D
PDS Biotechnology
Flag link:
Vera finally notches a win for Merck KGaA castoff in autoimmune kidney disease
Vera finally notches a win for Merck KGaA castoff in autoimmune kidney disease
Fierce Biotech
Vera Therapeutics
Merck KGaA
autoimmune kidney disease
atacicept
Flag link:
Merck KGaA outlines plan to rev up drug R&D
Merck KGaA outlines plan to rev up drug R&D
BioPharma Dive
Merck KGaA
drug development
R&D
Flag link:
Merck KGaA’s MilliporeSigma invests $286M to build out biosafety testing
Merck KGaA’s MilliporeSigma invests $286M to build out biosafety testing
Endpoints
Merck KGaA
MilliporeSigma
biosafety testing
Flag link:
CEOs of BioNTech, Bayer, Merck KGaA join German Chancellor Scholz in high-profile China visit
CEOs of BioNTech, Bayer, Merck KGaA join German Chancellor Scholz in high-profile China visit
Fierce Pharma
China
Pharma CEOs
Bayer
Merck KGaA
BioNTech
Flag link:
Systemic lupus erythematosus: major drug trials to watch in 2022 and 2023
Systemic lupus erythematosus: major drug trials to watch in 2022 and 2023
Clinical Trials Arena
clinical trials
systemic lupus erythematosus
AbbVie
ABBV-509
Eli Lilly
LY3471851
Merck KGaA
M5049
Swedish Orphan Biovitrum
emapalumab
Flag link:
Pfizer, Merck and J&J Back UK Startup Mining the Dark Genome for Autoimmune Therapies
Pfizer, Merck and J&J Back UK Startup Mining the Dark Genome for Autoimmune Therapies
BioSpace
Nucleome Therapeutics
funding
precision medicine
autoimmune diseases
Pfizer
JNJ
Merck KGaA
autoimmune disease
Flag link:
Merck KGaA in licensing deal with Nerviano Medical for PARP inhibitor
Merck KGaA in licensing deal with Nerviano Medical for PARP inhibitor
Seeking Alpha
Merck KGaA
Nerviano Medical Sciences
NS-293
PARP inhibitors
Flag link:
Merck KGaA continues expansion with $285M+ investment in 2 new projects in France and Germany
Merck KGaA continues expansion with $285M+ investment in 2 new projects in France and Germany
Endpoints
Merck KGaA
COVID-19
vaccines
France
Germany
drug manufacturing
Flag link:

Pages